Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2020 Sep 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Medica 2020 Sep 21

DOI: 10.23736/S0026-4806.20.07031-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia

Francesco LANZA 1 , Enrico MAFFINI 1, Francesco SARACENI 2, Evita MASSARI 3, Michela RONDONI 1, Giulia DAGHIA 1, Attilio OLIVIERI 2, Claudio CERCHIONE 4, Giovanni MARTINELLI 5

1 Hematology Unit & Romagna Transplant Network, “Santa Maria delle Croci” Hospital, Ravenna, Italy; 2 Hematology Unit, University of Ancona, Ancona, Italy; 3 Laboratory Service, AUSL Romagna, Cesena, Italy; 4 Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy; 5 Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy


PDF


Patients with acute lymphoblastic leukemia (ALL) are characterized by an unfavorable outcome in the majority of adult cases. Several clinical trials have confirmed the usefulness of a pediatric-type therapy applied to adult patients. Adults present with higher risk features at diagnosis that predispose them to chemotherapy resistance and disease relapse after an initial achievement of complete remission. The recent introduction of novel immune-targeted therapies, including monoclonal antibodies (MoAbs) targeting B cell-associated antigens such as CD19 (blinatumumab) and CD22 (inotuzumab), tyrosine kinase inhibitors targeting BCR-ABL1 tyrosine kinase, bispecific antibodies and chimeric antigen receptor T- cell therapy (CAR-T), circumvent B-ALL cell chemo-refractoriness through novel mechanisms of action, potentially eradicating minimal residual disease (MRD) and enabling more patients to receive allogeneic hematopoietic stem cell transplantation and to achieve a better clinical outcome.


KEY WORDS: ALL; Molecular alterations; Risk stratification; Chemotherapy; Inotuzumab; Blinatumumab; TKI-inhibitors

top of page